Surprising find

More than half of heart scans abnormal in hospitalised COVID-19 patients

Half of COVID-19 patients who received a heart scan in hospital showed abnormalities in heart function, according to new research funded by the British Heart Foundation (BHF).

The study, published in the European Heart Journal - Cardiovascular Imaging, found that around one in seven showed severe abnormalities likely to have a major effect on their survival and recovery. It also showed that one in three patients who received an echocardiography scan had their treatment changed as a result.

red neon sign in shape of a human heart

Image source: Unsplash/Alexandru Acea

The findings suggest that heart scans could prove crucial for identifying patients who may benefit from additional treatments to improve their COVID-19 recovery and prevent potential long-term damage to their heart. 

Researchers from the British Heart Foundation Centre of Research Excellence at the University of Edinburgh looked at echocardiogram results of 1216 patients from 69 countries with COVID-19. An echocardiogram is a type of ultrasound scan used to look at the heart in real-time at a patient’s bedside. The scan results were sourced from many COVID-19 hotspots around the world, allowing researchers to urgently understand the impact of COVID-19 on the heart while the pandemic was at its peak.

In the study, over half (55 per cent) of all patients, including those with pre-existing heart disease, showed abnormal changes to the way their heart was pumping, with around one in seven showing evidence of severe dysfunction. The majority (901) had no known heart disease before the study and showed similar changes. Almost half (46 per cent) and one in eight (13 per cent) showed abnormal changes and severe dysfunction respectively. These changes were observed for the first time during the patients’ COVID-19 illness and the researchers believe they could be due to the effects of the virus.

Severe COVID-19 illness can result in damage to the heart and circulatory system. We urgently need to understand more about why this is happening so we can provide appropriate care – both short and long term

Sonya Babu-Narayan

In the study, one third of patients had their treatment changed as a result of the echocardiogram. This included being given medicines for heart failure, or more careful control of fluids and therapy designed to support heart function – treatments which could help save lives. The researchers point out several limitations to their study given its observational design. During the pandemic the number of scans being carried out would have been carefully balanced with the risk of exposing staff, patients and equipment to the virus. Patients who received the scans were in hospital and had suspected heart complications, usually because they had abnormal blood markers reflecting heart damage. This study does not tell us how common heart changes are in people who did not receive a scan.

Professor Marc Dweck, British Heart Foundation Senior Lecturer and Consultant Cardiologist at the University of Edinburgh, said: “COVID-19 is a complex, multisystem disease which can have profound effects on many parts of the body, including the heart. Many doctors have been hesitant to order echocardiograms for patients with COVID-19 because it’s an added procedure which involves close contact with patients. Our work shows that these scans are important – they improved the treatment for a third of patients who received them. Damage to the heart is known to occur in severe flu, but we were surprised to see so many patients with damage to their heart with COVID-19 and so many patients with severe dysfunction. We now need to understand the exact mechanism of this damage, whether it is reversible and what the long-term consequences of COVID-19 infection are on the heart.”

Dr Sonya Babu-Narayan, Associate Medical Director at the British Heart Foundation and Consultant Cardiologist, said: “Severe COVID-19 illness can result in damage to the heart and circulatory system. We urgently need to understand more about why this is happening so we can provide appropriate care – both short and long term. This global study – carried out at the height of the pandemic – shows that we must be on the lookout for heart complications in people with COVID-19 so that we can adapt their treatment, if needed. BHF funded researchers across the UK are working tirelessly to help us answer many urgent questions about COVID-19. These include understanding why people with heart and circulatory disease are at increased risk, how the heart and circulation are impacted by COVID-19 and the indirect effects of the pandemic on people with heart and circulatory diseases. Their work, along with other scientists across the UK will be crucial for finding new treatments and determining the optimal way to care for people with COVID-19.”


Source: The BMJ

13.07.2020

Read all latest stories

Related articles

Photo

Cardiovascular Magnetic Resonance

Insight on the use of CMR in COVID-19 patients

The Society for Cardiovascular Magnetic Resonance (SCMR), a Society dedicated to improving cardiovascular health by advancing the field of cardiovascular magnetic resonance (CMR), has released a…

Photo

Reduced complications, death

COVID-19: The benefits of vitamin D

Adequate levels of vitamin D reduces complications and deaths among COVID-19 patients, reveals new research performed at the Boston University School of Medicine. Hospitalized COVID-19 patients who…

Photo

ESC: randomised trial

Covid-19 patients can safely continue taking heart drugs

Heart patients hospitalised with COVID-19 can safely continue taking angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), according to the BRACE CORONA trial…

Related products

Eppendorf – Mastercycler nexus X2

Research Use Only (RUO)

Eppendorf – Mastercycler nexus X2

Eppendorf AG
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH